Pfizer (PFE) Long-Term Debt Issuances (2009 - 2025)

Pfizer's (PFE) quarterly Long-Term Debt Issuances came in at $6.0 billion in Q4 2025, up 500.9% quarter-over-quarter from $997.0 million in Q4 2021.

Analysis

Pfizer (PFE) Long-Term Debt Issuances (2009 - 2025) Analysis & Trends

Pfizer (PFE) has reported Long-Term Debt Issuances for 13 consecutive years, with $6.0 billion the latest figure, recorded in Q4 2025.

On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $6.0 billion in Q4 2025; TTM through Dec 2025 was $6.0 billion, a N/A change from a year earlier, with the FY2025 full-year figure at $9.7 billion, changed N/A from the prior year.
Long-Term Debt Issuances was $6.0 billion for Q4 2025 at Pfizer, up from $997.0 million in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $6.0 billion in Q4 2025 and troughed at $997.0 million in Q4 2021.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Johnson & Johnson	663.08 Bn	642.33 Bn	17.26 Bn	-
2	AbbVie	453.04 Bn	446.51 Bn	12.70 Bn	-
3	Merck	370.87 Bn	363.78 Bn	12.21 Bn	-
4	Novartis Ag	305.29 Bn	298.00 Bn	11.24 Bn	1.98 Bn
5	Pfizer	162.10 Bn	150.70 Bn	10.94 Bn	-
6	Sanofi	53.95 Bn	46.98 Bn	10.79 Bn	4.88 Bn
7	Revolution Medicines	45.00 Bn	45.00 Bn	-	-
8	BeOne Medicines	40.49 Bn	35.39 Bn	1.53 Bn	-
9	Incyte	25.47 Bn	20.94 Bn	1.57 Bn	-
10	United Therapeutics	20.81 Bn	18.15 Bn	683.80 Mn	-

Historic Data

Download Data